论文部分内容阅读
目的探讨血清C反应蛋白与白蛋白比值对晚期结直肠癌患者预后的判断价值。方法 64例晚期结直肠癌患者,均进行2年随访,根据患者存活状态分为存活组和死亡组,各32例。比较两组患者初次入院时血清C反应蛋白、白蛋白及血清C反应蛋白/白蛋白比值,分析血清C反应蛋白、白蛋白及血清C反应蛋白/白蛋白比值预测患者生存的ROC曲线。结果初次入院时死亡组血清C反应蛋白、白蛋白、血清C反应蛋白/白蛋白比值分别为(26.35±8.54)mg/L、(26.31±4.58)mg/L、(1.02±0.24),存活组分别为(18.52±7.98)mg/L、(31.58±5.19)mg/L、(0.75±0.36);死亡组初次入院时血清C反应蛋白、血清C反应蛋白/白蛋白比值高于存活组,白蛋白低于存活组,差异有统计学意义(P<0.05)。血清C反应蛋白、白蛋白及血清C反应蛋白/白蛋白比值预测患者生存的ROC曲线存在明显差异,血清C反应蛋白/白蛋白比值的曲线下面积(AUC)明显高于血清C反应蛋白、白蛋白,差异有统计学意义(P<0.05)。结论结直肠癌的发展过程中检测血清C反应蛋白与白蛋白比值可以预测晚期结直肠癌患者预后,值得在临床上扩大样本量进一步研究。
Objective To investigate the value of serum C-reactive protein and albumin in the prognosis of patients with advanced colorectal cancer. Methods 64 cases of advanced colorectal cancer patients were followed up for 2 years, according to the survival status of the patients were divided into survival group and death group, 32 cases each. Serum C-reactive protein, albumin and serum C-reactive protein / albumin ratio were compared between the two groups. ROC curves of serum C-reactive protein, albumin and serum C-reactive protein / albumin ratio were calculated. Results The serum C-reactive protein, albumin and serum C-reactive protein / albumin ratio in the death group at the initial admission were (26.35 ± 8.54) mg / L, (26.31 ± 4.58) mg / L and (1.02 ± 0.24) (18.52 ± 7.98) mg / L, (31.58 ± 5.19) mg / L and (0.75 ± 0.36), respectively. The serum C-reactive protein and serum albumin / serum albumin ratio were higher in the death group than in the surviving group The protein was lower than the survival group, the difference was statistically significant (P <0.05). Serum C-reactive protein, albumin and serum C-reactive protein / albumin ratio predict the survival of patients with ROC curves were significantly different, serum C-reactive protein / albumin area under the curve (AUC) was significantly higher than serum C-reactive protein, Protein, the difference was statistically significant (P <0.05). Conclusion The detection of serum C - reactive protein and albumin ratio during the development of colorectal cancer can predict the prognosis of patients with advanced colorectal cancer. It is worth further exploration in expanding the sample size clinically.